JP2024501767A - シアリダーゼ－ｈｅｒ２－抗体融合タンパク質、及びその使用方法 - Google Patents

シアリダーゼ－ｈｅｒ２－抗体融合タンパク質、及びその使用方法 Download PDF

Info

Publication number
JP2024501767A
JP2024501767A JP2023540918A JP2023540918A JP2024501767A JP 2024501767 A JP2024501767 A JP 2024501767A JP 2023540918 A JP2023540918 A JP 2023540918A JP 2023540918 A JP2023540918 A JP 2023540918A JP 2024501767 A JP2024501767 A JP 2024501767A
Authority
JP
Japan
Prior art keywords
wild
residue
type human
position corresponding
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023540918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501767A5 (https=
JPWO2022150516A5 (https=
Inventor
パン，リー
ツァオ，リーチー
エイ． シェルケ，サンディプ
Original Assignee
パレオン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パレオン ファーマシューティカルズ インコーポレイテッド filed Critical パレオン ファーマシューティカルズ インコーポレイテッド
Publication of JP2024501767A publication Critical patent/JP2024501767A/ja
Publication of JP2024501767A5 publication Critical patent/JP2024501767A5/ja
Publication of JPWO2022150516A5 publication Critical patent/JPWO2022150516A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023540918A 2021-01-06 2022-01-06 シアリダーゼ－ｈｅｒ２－抗体融合タンパク質、及びその使用方法 Withdrawn JP2024501767A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163134411P 2021-01-06 2021-01-06
US63/134,411 2021-01-06
US202163217998P 2021-07-02 2021-07-02
US63/217,998 2021-07-02
PCT/US2022/011499 WO2022150516A1 (en) 2021-01-06 2022-01-06 Sialidase-her2-antibody fusion proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024501767A true JP2024501767A (ja) 2024-01-15
JP2024501767A5 JP2024501767A5 (https=) 2025-01-23
JPWO2022150516A5 JPWO2022150516A5 (https=) 2025-01-23

Family

ID=82357542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540918A Withdrawn JP2024501767A (ja) 2021-01-06 2022-01-06 シアリダーゼ－ｈｅｒ２－抗体融合タンパク質、及びその使用方法

Country Status (9)

Country Link
US (1) US20240059792A1 (https=)
EP (1) EP4274892A4 (https=)
JP (1) JP2024501767A (https=)
KR (1) KR20230138473A (https=)
AU (1) AU2022206263A1 (https=)
CA (1) CA3173668A1 (https=)
IL (1) IL304233A (https=)
MX (1) MX2023008027A (https=)
WO (1) WO2022150516A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037175A1 (zh) 2024-08-16 2026-02-19 上海宝济药业股份有限公司 靶向靶细胞的复合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136167A1 (en) * 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081801B2 (en) * 2013-04-12 2018-09-25 Danmarks Tekniske Universitet Mutant sialidase having trans-sialidase activity for use in production of sialylated glycans
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells
WO2020172072A1 (en) * 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
CA3135531A1 (en) * 2019-04-30 2020-11-05 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
US20240067729A1 (en) * 2021-01-06 2024-02-29 Palleon Pharmaceuticals Inc. Anti-pd-l1 antibodies and fusion proteins thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136167A1 (en) * 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法

Also Published As

Publication number Publication date
IL304233A (en) 2023-09-01
MX2023008027A (es) 2023-09-05
US20240059792A1 (en) 2024-02-22
EP4274892A4 (en) 2025-03-12
CA3173668A1 (en) 2022-07-14
WO2022150516A1 (en) 2022-07-14
KR20230138473A (ko) 2023-10-05
AU2022206263A1 (en) 2023-07-20
EP4274892A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
JP2024026296A (ja) 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
JP7777988B2 (ja) 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
JP2024501771A (ja) 抗ｐｄ－ｌ１抗体及びその融合タンパク質
US20230265406A1 (en) Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same
US20220372458A1 (en) Sialidase-pd-l1-antibody fusion proteins and methods of use thereof
JP2024501767A (ja) シアリダーゼ－ｈｅｒ２－抗体融合タンパク質、及びその使用方法
US20220380742A1 (en) Sialidase-cd20-antibody fusion proteins and methods of use thereof
US20220387616A1 (en) Sialidase-her2-antibody fusion proteins and methods of use thereof
JP2024501770A (ja) シアリダーゼ－ｐｄ－１－抗体融合タンパク質及びその使用方法
JP2022538895A (ja) 組換えシアリダーゼおよびその使用方法
CN116940675A (zh) 唾液酸酶-her2-抗体融合蛋白及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251229